Drug | Indication |
---|---|
Rilpivirine hydrochloride | Human immunodeficiency Virus |
Spinosad | Lice |
Telaprevir | Hepatitis C |
Brentuximab vedotin | Hodgkin lymphoma |
Brentuximab vedotin | Large-cell lymphoma |
Clobazam | Lennox-Gastaut syndrome |
Boceprevir | Hepatitis C |
Belimumab | SLE |
Lucinactant | Respiratory distress syndrome |
Taliglucerase alfa | Gaucher disease |
Ivacaftor | Cystic fibrosis |
Crofelemer | Patients with diarrhea and Human immunodeficiency Virus infection on antiretroviral therapy |
Teriflunomide | Relapsing multiple sclerosis |
Cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | Human immunodeficiency Virus |
Lomitapide mesylate | Homozygous familial hypercholesterolemia |
Mipomersen sodium | Homozygous familial hypercholesterolemia |
Dimethyl fumarate | Relapsing remitting multiple sclerosis |
Macitentan | Pulmonary arterial hypertension (WHO group 1) |
Dolutegravir sodium | Human immunodeficiency Virus |
Riociguat | Persistent/recurrent CTEPH (WHO group 4) after surgery or inoperable CTEPH to improve exercise capacity and WHO functional class |
Riociguat | Pulmonary arterial hypertension (WHO group 1) to improve exercise capacity, WHO class, delay functional worsening |
Simeprevir sodium | Hepatitis C |